ArticleAmerican journal of translational research2022
Posterior scleral contraction to treat myopic traction maculopathy at different stages.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Subthreshold micropulse laser for subretinal fluid after vitrectomy in myopic traction maculopathy: a pilot randomized controlled trial.Lasers in medical science · 2026Trial
- Long-term outcomes of early posterior scleral contraction for myopic macular retinoschisis in patients up to 30 years.Frontiers in medicine · 2026Article
- Efficacy of posterior scleral reinforcement in the management of myopic traction maculopathy: a single-arm retrospective study.BMC ophthalmology · 2025Article
- Application of 3D MRI and SS-OCT/OCTA in Assessment of Posterior Scleral Contraction for Myopic Traction Maculopathy.Translational vision science & technology · 2025Article
- Bibliometric analysis of hotspots and trends of global myopia research.International journal of ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe aimed to evaluate anatomical and functional outcomes and determine posterior scleral contraction (PSC) timing in treating myopic traction maculopathy (MTM).
methodsThis is a retrospective study of MTM patients undergoing PSC with genipin cross-linked strip at a single hospital site. Differences in demographic and clinical characteristics were compared among three groups defined by the MTM staging system. All patients were followed up for at least one year postoperatively. The best-corrected visual acuity (BCVA), macular hole diameter, axial length (AL), optical coherence tomography findings, and the complications were evaluated. Additionally, regression analyses were performed to account for confounders.
resultsSixty-one MTM patients (24 eyes at stage 2, 22 eyes at stage 3, and 18 eyes at stage 4) were included. The macular holes were closed in 16 eyes (66.7%), 13 eyes (59.0%), and 11 eyes (61.1%) at stage 2, stage 3, and stage 4, respectively. PSC improved the BCVA in patients at each stage (all
conclusionsPSC is safe and effective in treating MTM at different stages. Early PSC intervention will have more significant visual benefits.
Indexed as
Identifiers
35173857PMC8829633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.